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Abstract: 
Simian virus 40 large T-antigen (SV40 LT-Ag) is a 708 amino acid nuclear phosphoprotein. Among many functions of LT-Ag is its 
ability to perform as an ATPase-helicase, catalyzing the unwinding of viral genome during replication. The LT-Ag has been employed 
in the studies of helicase structure and function, and has served as a model helicase for the screening of antiviral drugs that target viral 
helicase. In this study, using in vitro enzyme assays and in silico computer modeling, we screened a batch of 18 fluoroquinolones to 
assess their potential as antivirals by virtue of their inhibition of the LT-Ag helicase. We found all fluoroquinolones to be inhibitory to 
the helicase activity of LT-Ag. In our docking analysis, most of these tested drugs showed similarity in their interactions with LT-Ag. 
Our study shows the potential of fluoroquinolones as antiviral drugs and of SV40 LT-Ag as a model protein for screening drugs 
against viral helicases.  
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Background: 
Simian virus 40 (SV40) is a small, non-enveloped DNA virus [1]. 
The virus’ genome comprises two sets of genes: late and early 
expressed [2]. The late expressed genes encode structural proteins 
necessary for viral assembly; these include three capsid proteins 
VP1, VP2, VP3 and a maturation protein agnoprotein [2]. The 
early expressed genes encode proteins required for viral 
replication. This set includes the small and large T antigens (ST-
Ag and LT-Ag, respectively) [3]. The SV40 LT-Ag is a 708 amino 
acid nuclear phosphoprotein, with multiple biochemical activities 
[4]. The LT-Ag is able to transform many cell types; its 
transforming ability is mainly dependent upon its interaction 
with cellular factors including retinoblastoma and p53 tumor 
suppressor proteins [3]. The LT-Ag also acts as a regulator of 
viral and cellular gene expression, and as an initiator of viral 
DNA replication [5, 6]. The LT-Ag binds to specific sites in the 
region of SV40 replication origin and promotes the local 
unwinding of DNA. LT-Ag recruits cellular DNA replication 
proteins to the site, which include Topoisomerase I, replication 
protein A, and DNA polymerases, and thus promotes SV40 DNA 
replication [7]. 
 
Among many functions of LT-Ag is also its ability to perform as 
an ATPase-helicase, catalyzing the unwinding of viral genome 
during replication, harvesting the energy required for this 
process by means of ATP hydrolysis [6]. The SV40 LT-Ag is a 
member of superfamily 3 of helicases, which consists of ring 
forming helicases [7]. In addition to oncology research, LT-Ag 
has been employed in the studies of helicase structure and 
function. The LT-Ag has served as a model helicase also for the 
screening of antiviral drugs that target viral helicases [8]. In our 
previous study, LT-Ag was used as a model helicase to develop a 
non-radioactive helicase assay [9]. For the current study, using in 
vitro and in silico methods, we screened a batch of 18 
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fluoroquinolones to assess their potential as antivirals by virtue 
of their binding to, and inhibition of, the LT-Ag helicase.  
 
Methodology: 
Helicase Assay: 
Purified SV40 LT-Ag was purchased from CHIMERx, USA. As 
described previously [9], the helicase substrate was prepared by 
mixing single strands of complimentary oligonucleotides in 1:1 
ratio to a final concentration of 20 µM each, heated to 95°C for 5 
min, and then allowed to anneal by gradual cooling to room 
temperature for 1 hr. Typically, each helicase reaction contained 
20µl 5x helicase buffer (200mM Tris pH-7.6, 25mM MgCl2, 20mM 
DTT, 125mM KCl, 10% glycerol and 0.5µg/ulBSA), 1mM ATP, 
10µM DNA oligo substrate, 1x SYBR Green I and 1.44µM purified 
helicase, in a total volume of 100µl. The reaction was incubated at 
37°C for 30 min and carried out in triplicates. Adding 4µl of 0.5M 
EDTA stopped reaction. Fluorescence was measured using 
Chameleon Fluorescence Reader 2 (Hidex, Finland), at 
excitation/emission 492/535 nm. For calculating the helicase 
activity, readings were corrected by subtracting the background 
fluorescence of a SYBR Green-only blank reaction mixture from 
the fluorescence of the sample. The enzyme activity was then 
expressed as percentage of unwound substrate as follows:  
Percentage of unwound substrate = [(y-x)/y]*100 
Where x and y represent the fluorescence of reaction, 
respectively, with and without any added helicase. 
 
Enzyme Inhibition Assay: 
Inhibition assays for helicase activity were performed as reported 
previously [9, 10]. Eighteen fluoroquinolones, in concentrations 
of 0.1, 1, 10 or 100 µM, were tested for their inhibition on LT-Ag 
helicase activity. These tested fluoroquinolones were: 
Levofloxacin, Ciprofloxacin, Ofloxacin, Balofloxacin, Fleroxacin, 
Enoxacin, 8Hydroxquinolinol, Pefloxacin, Lomefloxacin, 
Nalidixic acid, Enrofloxacin, Cinoxacin, Difloxacin, Flumiquine, 
8Quinolinol, Sparfloxacin, Norfloxacin, and Moxifloxacin.  The 
results were expressed as percent inhibition observed in the 
presence of the inhibitor, taking LT-Ag helicase activity as 100% 
in the absence of any added inhibitor. 
 
Docking Studies: 
To analyze the interactions between LT-Ag and the selected 
fluoroquinolones, crystal structure of SV40 LT-Ag (PDB ID: 
1SVO) was obtained from Protein Data Bank 
(http://www.rcsb.org), while the SDF files of the 
fluoroquinolones were obtained from the Pubchem library of the 
NCBI database (http://www.ncbi.nlm.nih.gov/pccompound). 
The SDF files were subsequently converted to mol2 format by 
using OpenBabel GUI [11]. The binding pocket for the drug was 
predicted using Molegro Virtual Docker (MVD) software. To select 
the helicase-binding site, coordinates of the binding sphere were 
designated between Glu473 and Lys445, whereas the radius of 
search sphere was kept at default setting, i.e., 10Å. To predict 
protein-ligand interactions, Lead IT or FlexX version 2.0, software 
was employed [12, 13]. The docking was performed using the 
default parameters of the program, and the Single Interaction 
Scan algorithm of Lead IT was used for this analysis. This 
software generates more than 100 docking poses and presents 
them in ascending order with respect to docking energy. To 
verify these results, the same analyses were also performed with 
MVD software.  
 
Results: 
Inhibition of LT-Ag Helicase Activity by Fluoroquinolones: 
The LT-Ag helicase activity was measured in the presence of 0.1, 
1.0,10 and 100μM fluoroquinolone. Percent inhibition of LT-Ag 
helicase activity by all 18 fluoroquinolones was observed to 
follow almost a linear trend (Figure 1). At 100μM concentration, 
all drugs except Enrofloxacin, Flumiquine, Sparfloxacin and 
8Quinolinol, showed 60-90% inhibition of helicase activity. 
Similarly, at 10μM concentration, all fluoroquinolones, except 
Sparfloxacin and 8Quinolol, showed 40-80% inhibition of helicase 
activity. With the exception of Balofloxacin, Ofloxacin, 
8Hydroquinolol, and, Sparfloxacin, all fluoroquinolones showed 
30%-60% inhibition of LT-Ag helicase activity at 1 μM (Figure 1). 
 
Docking studies: 
The model of SV40 LT-Ag (PDB ID: 1SVO) was docked 
individually with each of the above-mentioned 18 
fluoroquinolones. Each fluoroquinolone was docked deep into 
the active site of LT-Ag helicase protein molecule. Coordinates of 
the LT-Ag binding sphere were designated between Glu473 and 
Lys445. Based on the lowest docking energy, 6 fluoroquinolones, 
namely, Balofloxacin, Ofloxacin, Pefloxacin, Lomefloxacin, 
Ciprofloxacin, and Levofloxacin, were selected for detailed 
analyses of their interactions with LT-Ag (Table 1). Except for 
Lomefloxacin and Ofloxacin, all six fluoroquinolones showed H-
bond interactions with Gly445 and Glu473 in the binding pocket 
of LT Ag (Table2 and Figure 2). Although it did not form H-bond 
interactions, amino acid Leu440 was found in the binding pocket 
of all fluoroquinolones except Lome- and O-floxacin (Figure 2). 
Overall, therefore, the interactions made by Lomefloxacin and 
Ofloxacin were somehow unique compared to other drugs (Table 
2 and Figure 2). Based on the free energy values, the affinity of 
the six drugs for LT-Ag was found to be in the following order: 
Balofloxacin>Pefloxacin>Lomefloxacin> Ciprofloxacin > 
Levofloxacin >Ofloxacin (Table 1). The same order was 
recapitulated when the docking energy of these fluoroquinolones 
were calculated using a different software, namely, Molegro 
(Table 1). Overall, Molegro recapitulated the interactions between 
fluoroquinolones and SV40 LT-Ag (data not shown).  
 
Table 1: Docking energies of Fluoroquinolone-LT Ag complexes: Docking 
energy scores (KJ/mol) werepredicted usingFlexXand Molegrosoftware. 
The drugs are arranged in ascending order of the docking energy scores 
of their complexes with SV40 LT-Ag. The energy scores predicted for each 
drug-protein complex by the two softwares, although on different scales, 
were in agreement with each other. 
Docking Energy (KJ/mol) Ligand 
FlexX Molegro 
Balofloxacin -16.4 -73.4 
Pefloxacin -16.1 -68.2 
Lomefloxacin -15.6 -65.7 
Ciprofloxacin -15.0 -61.4 
Levofloxacin -14.0 -60.9 
Ofloxacin -13.6 -59.0 
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Table 2: LT-Ag amino acid residues interacting with Fluoroquinolones: 
The table shows amino acid residues constituting the binding pocket of 
LT-Ag.  Amino acids shown in bold were found to make H-bond 
interactions with fluoroquinolones, while the remaining amino acid 
residues represent residues residing in the binding pocket. 
 
Ligand Interacting Amino acid Residues 
Balofloxacin Glu473, Gly445, Lys446, Leu440 Ala447 
Pefloxacin Lys446, Gly445 Glu473, Leu440 Ala447 
Lomefloxacin Glu460, Ala447, Lys446, Leu448 Val463 
Ciprofloxacin Gly445, Glu473, Leu440, Ala447, Lys446 
Levofloxacin Gly445, Glu473, Ala447, Leu440, Lys446 
Ofloxacin Glu460, Asn449, Glu473, Asp474 
 
Figure1: LT-Ag helicase inhibition by fluoroquinolones: Bars represent percent inhibition of LT-Ag helicase activity treated with 
0.01, 0.1 µM, 1.0 or 10µM of the fluoroquinolone. With few exceptions, most of the fluoroquinolones exhibited 30–70% inhibition of LT-
Ag helicase activity at 1.0µM and 10µM concentration. Each bar represents mean of triplicates ± SEM. 
 
Discussion: 
In this study we have used SV40 LT-Ag as a model viral helicase 
and have explored the inhibitory interactions of 
fluoroquinoloneson with this enzyme using in vitro as well as in 
silico approaches. We tested the activity of a panel of 18 
fluorquinolones using a helicase assay and found all of them to 
inhibit the helicase activity of LT-Ag. Docking of these 
fluoroquinolones on LT-Ag was also performed using in silico 
methods. Based on the free energy values, 6 fluoroquinolones 
were found to interact most strongly with LT-Ag, with their 
binding affinities in the following order: 
Balofloxacin>Pefloxacin>Lomefloxacin>Ciprofloxacin>Levofloxa
cin >Ofloxacin. Docking analysis identified certain amino acids in 
the LT-Ag active site, namely, Gly445, Glu473, and Leu440 that 
were found to interact frequently with most of the six selected 
fluoroquinolones. For this study, we employed the non-
radioactive assay that we have previously published [10].  In this 
assay, 18 different fluoroquinolones were tested on LT Ag 
helicase activity. All of the tested drugs showed inhibition of 
helicase activity to some degree. Most fluoroquinolones showed 
inhibition of 40%-80% at 10uM and 30%-60% at 1uM.  In our 
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previously reported study on HCV NS3 helicase, all 
fluoroquinolones we tested showed inhibition of NS3 helicase 
activity as well, with Ofloxacin, Fleroxacin, Enoxacin, 
8Hydroxyquinolinol, Difloxacin, Flumiquine and 8Quinolinol 
exhibiting 10-40% inhibition of HCV NS3 helicase at 0.1µM 
concentration [11]. In another study, helicase activity of SV40 LT-
Ag was inhibited by Levo-, Cipro-, Trovo-, and O-floxacin [8]. 
The current results are therefore consistent with previous reports. 
 
 
Figure 2: Docked conformation of Fluoroquinolones in the binding cavity of LT-Ag: Docked models in 2D format, generated by 
FlexX, showing the binding pocket of LT-Ag with docked conformations of (A) Balofloxacin, (B) Pefloxacin, (C) Lomefloxacin, (D) 
Ciprofloxacin, (E) Levofloxacin, and (F) Ofloxacin. Broken lines indicate H bonding. 
 
Although all fluoroquinolones were found inhibitory to both the 
viral helicases, as expected, the individual fluoroquinolones 
behaved differently with respect to the level of inhibition 
observed on HCV NS3 and SV40 LT-Ag. Since the architecture of 
the helicase active site represents diversification among different 
viral helicases, the nature of their interaction with 
fluoroquinolones was expected to differ accordingly. A deeper 
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understanding of the differential interaction of 
fluororoquinolones on different helicases may be obtained by 
analyzing crystal structures of helicase-fluoroquinolone 
complexes and/or by studying the effect of amino acid mutations 
in the active site of LT-Ag. For the current study, we adopted an 
in silico approach to further dissect the interactions of 
fluoroquinolones at the LT-Ag active site. 
 
Computer docking models of fluoroquinolone-LT-Ag helicase 
also revealed certain key functional groups of fluoroquinolone 
that were involved in their mutual interaction with LT-Ag 
helicase. The docked models of fluoroquinolones and LT-Ag 
showed that the piperazinyl moiety at position 7, carboxylic acid 
at position 3 and oxoquinoline at position 4 in the 
fluoroquinolone molecule were mostly involved in interaction 
with the amino acid residues of LT-Ag. The docking output 
reflected binding efficiency of LT-Ag and fluoroquinolones. The 
binding affinity of Balofloxacin was the highest followed by 
affinities for Pefloxacin, Lomefloxacin, Ciprofloxacin, 
Levofloxacin, and Ofloxacin (-16.4, -16.1, -15.6, -15.0, -14.0, and -
13.6, kJ/mol, respectively), as predicted by FlexX (Table 1). The 
same trend was recapitulated when the docking of these drugs 
was performed using Molegro. All of these fluoroquinolones also 
showed 60-70% inhibition of helicase activity at 10µM 
concentration in in vitro helicase assay (Figure 1). The molecular 
interaction between Ofloxacin and SV40 LT-Ag was found to be 
weakest as judged by docking energy scores  (-13.6), which was 
in agreement with in vitro assay results, where at 10µM 
concentration it showed less than 60% inhibition of helicase 
activity (Figure 1). It may be concluded, therefore, that the energy 
scores roughly correlated with the performance of 
fluoroquinolones in the invitro assays. On a deeper level, 
discrepancies in a drug’s in situ and in vitro behavior may also be 
attributed to the behavior of the drug in solution, and the effects 
of environmental factors, such as pH and temperature. 
Interestingly, Ofloxacin and Lomefloxacin showed interactions 
that were unique from all the other fluoroquinolones we studied. 
Since, structurally, Ofloxacin and Lomefloxacin are not 
remarkably different from the rest of the drugs; it is possible that 
the in situ spatial orientation of these two fluoroquinolones 
differs from the other drugs we studied. This may be further 
explored by deeper analysis of docked fluroquinolone-LT-Ag 
complexes. It would be interesting to design in silico derivatives 
of fluoroquinolones, combining features of Ofloxacin and 
Lomefloxacin with other fluoroquinolones, and study their 
docked complexes with LT-Ag and other helicases. This exercise 
may provide fluroroquinolone derivatives that inhibit the 
helicase activity more strongly than the existing drugs. 
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